|Home||Company Search||Related Articles||Forum (new!)|
|Company||GlaxoSmithKline [Company Info]|
|Track this Company (an email will be sent to you everytime a report is filed about this company)|
|29th Mar 2006||Questionable Practice||Glaxo agrees US Paxil settlement|
|GlaxoSmithKline (GSK) has agreed to pay $14m (£8m) to settle US claims that it fraudulently tried to delay competitors to anti-depressant drug Paxil.
It agreed the deal with Eliot Spitzer, New York Attorney General, who brought the case on behalf of 49 states.
GSK was accused of using frivolous patent-infringement lawsuits against generic producers of Paxil, keeping the drug's cost higher than necessary.
In reaching the deal, GSK said it denied any wrongdoing or liability.
"We made the decision that settling was appropriate to avoid the expense and distraction of protracted litigation," a company spokeswoman said.
The settlement will cover the cost of drug purchases by Medicaid, the state and federally funded medical programme for low income patients.
"GSK used the courts to hold onto a monopoly for a popular drug and the end result was that consumers - including Medicaid - paid more than they should have," said Jay Nixon, Missouri Attorney General, in a statement.
The company reached a separate deal with Mr Spitzer in 2004 to settle claims that it withheld negative information about Paxil, which is marketed as Seroxat in many markets.
As part of the agreement, it agreed to publish results of clinical trials of new drugs.
|Other Reports on GlaxoSmithKline|
|29th Jan 2007||Questionable Practice||GlaxoSmithKline||GSK hid paxil suicide link|
|10th Aug 2006||Other Issue||GlaxoSmithKline||Glaxo pays $70m to end price row|
|18th Mar 2005||Other Issue||GlaxoSmithKline||Glaxo shares dip on factory probe|
|22nd Sep 2004||Questionable Practice||GlaxoSmithKline||Glaxo drops appeal in Aids drug pricing case|
|6th Sep 2004||Other Issue||GlaxoSmithKline||GSK faces anti-depressant lawsuit|
|19th May 2004||Other Issue||GlaxoSmithKline||New York sues GlaxoSmithKline|
|11th May 2004||Fraud Investigation||GlaxoSmithKline||GlaxoSmithKline faces antitrust investigation|
|22nd Jan 2004||Fraud Investigation||GlaxoSmithKline||$11.1 Million settlement|
|8th Jan 2004||Questionable Practice||GlaxoSmithKline||£1.5bn Tax Bill|
|16th Dec 2003||Questionable Practice||GlaxoSmithKline||Glaxo's CEO to scoop 5.7 mln stg a year|
|25th Jun 2003||Questionable Practice||GlaxoSmithKline||FDA tells Glaxo to pull misleading Flonase ads|
|25th Jun 2003||Questionable Practice||GlaxoSmithKline||Ordered to pull misleading adverts|
|Related Reports from the Pharamaceutical Industry|
|Bayer||Fraud Investigation||$11.1 Million settlement|
|AstraZeneca||Fraud Investigation||Fined for Medicaid Fraud|
|Pfizer||Questionable Practice||Pfizer claims Britons denied treatment|
|Pfizer||Questionable Practice||Pfizer to use DART for online campaigns|
|AstraZeneca||Fraud Investigation||$355m fraud fine|
|© 2006 Corp-Ethics.com | Corporate Ethics|